Jonathan P Jarow

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop
    Jonathan P Jarow
    CDER Office of Medical Policy, Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 88:8-13. 2016
  2. doi request reprint Medical devices: US medical device regulation
    Jonathan P Jarow
    US Food and Drug Administration, Silver Spring, Md Electronic address
    Urol Oncol 33:128-32. 2015
  3. doi request reprint Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop
    Jonathan P Jarow
    Office of Hematology and Oncology Products, U S Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 83:975-8. 2014
  4. doi request reprint Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop
    Jonathan P Jarow
    Office of Hematology and Oncology Products, Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 83:262-4. 2014
  5. doi request reprint Variability of semen parameters with time in placebo treated men
    Jonathan P Jarow
    Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
    J Urol 189:1825-9. 2013
  6. doi request reprint Use of biomarkers to assess tissue specific androgen adequacy: defining male hypogonadism
    Jonathan P Jarow
    Division of Reproductive and Urologic Products, Office of New Drugs, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    J Urol 189:633-7. 2013

Detail Information

Publications6

  1. doi request reprint Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop
    Jonathan P Jarow
    CDER Office of Medical Policy, Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 88:8-13. 2016
    ..The purpose of this workshop was to discuss potential indications, current available evidence, and designs for future trials to provide the evidence needed by patients and providers to decide how and when to use PGA...
  2. doi request reprint Medical devices: US medical device regulation
    Jonathan P Jarow
    US Food and Drug Administration, Silver Spring, Md Electronic address
    Urol Oncol 33:128-32. 2015
    ..Devices that are not legally marketed are permitted to be used for clinical investigation purposes in the United States under the Investigational Device Exemptions regulation. ..
  3. doi request reprint Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop
    Jonathan P Jarow
    Office of Hematology and Oncology Products, U S Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 83:975-8. 2014
    ..FDA intends to develop a set of principles that can be used to promote the development of new products or devices for the treatment of this disease. ..
  4. doi request reprint Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop
    Jonathan P Jarow
    Office of Hematology and Oncology Products, Food and Drug Administration, Silver Spring, Md Electronic address
    Urology 83:262-4. 2014
    ..There have been only 3 drug approvals for NMIBC in the last 30 years, and product development for this disease has been stymied by difficulties in trial design and patient accrual...
  5. doi request reprint Variability of semen parameters with time in placebo treated men
    Jonathan P Jarow
    Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
    J Urol 189:1825-9. 2013
    ..We describe the variability of semen parameters with time in normal men receiving placebo. We also report the impact of season and geographic region, among other variables, on these parameters...
  6. doi request reprint Use of biomarkers to assess tissue specific androgen adequacy: defining male hypogonadism
    Jonathan P Jarow
    Division of Reproductive and Urologic Products, Office of New Drugs, Food and Drug Administration, Silver Spring, Maryland 20993, USA
    J Urol 189:633-7. 2013
    ..The criteria for normal testosterone have been established by expert consensus rather than by evidence. We determined whether a cutoff point for normal could be established using biomarkers...